Today: 1 May 2026
Charles Schwab stock slips after earnings pop as analysts lift targets
23 January 2026
2 mins read

Charles Schwab stock slips after earnings pop as analysts lift targets

New York, Jan 23, 2026, 14:30 EST — Regular session

  • Charles Schwab shares slipped roughly 1.3% to $102.71 in afternoon trading, moving between $104.05 and $101.25 earlier.
  • After the broker reported higher quarterly profit driven by stronger interest income and trading, the stock closed Thursday at $104.05.
  • Following the results, Barclays and Jefferies both lifted their price targets this week.

Shares of The Charles Schwab Corporation (SCHW.N) slipped 1.3% to $102.71 in Friday afternoon trading, after peaking at $104.05 earlier. The stock dropped $1.34 on the session, with roughly 5.0 million shares changing hands.

The pullback comes as investors zero in on two key drivers of brokerage earnings: interest income from client cash and trading volume. Both factors can swing rapidly with volatile markets or shifting views on U.S. interest rate levels.

Schwab reported a jump in fourth-quarter profit on Wednesday, fueled by a surge in interest income and robust trading revenue amid volatile markets. Net revenue climbed 19% to $6.34 billion, just shy of the $6.37 billion consensus estimate. Net income rose to $2.46 billion, or $1.33 per share, while net interest revenue surged over 25% to $3.17 billion.

Schwab reported total client assets hitting a record $11.90 trillion by the end of 2025, with client accounts rising 6% to 46.5 million. CEO Rick Wurster highlighted $519 billion in core net new assets added last year. CFO Mike Verdeschi noted $2.7 billion in share buybacks during Q4 and confirmed a deal to acquire Forge Global, expected to close in the first half of 2026.

The stock climbed into Thursday, closing 2.22% higher at $104.05. Volume topped its recent average, with shares ending less than 1% shy of their 52-week peak. Schwab edged out several financial rivals, even as the broader market gained.

Analysts are warming up to the post-earnings outlook. Barclays bumped up Schwab’s price target to $125 from $120, maintaining an Overweight rating. Analyst Benjamin Budish described Schwab’s 2026 forecast as “conservative.” TipRanks

Jefferies bumped its target up to $122 from $121, keeping a Buy rating intact. The upgrade came on the back of stronger Q4 operating results and record-high client assets. The firm also slightly raised its earnings estimates for 2026 and 2027 following the update.

The broader market was mixed on Friday. Mega-cap tech shares pushed the S&P 500 and Nasdaq higher, but a steep fall in Intel and renewed geopolitical concerns capped risk appetite, according to a Reuters market report.

For Schwab, cash and rates still dominate the market’s focus. Net interest revenue, which is the gap between earnings on assets and costs on liabilities, can shrink in a low-rate environment. Yet, cheaper margin borrowing in such conditions can also boost trading activity.

But it can flip the other way. If rates drop quicker than investors anticipate, or if clients move idle cash into better-yielding options, the boost from interest income might fade despite markets appearing solid. A steep equity sell-off would drag down asset-based fees and potentially dampen trading activity.

The upcoming key event is the Federal Reserve’s meeting on Jan. 27–28, with the policy decision expected on Jan. 28. Traders are set to focus on short-term yields immediately following the announcement, and whether Schwab’s stock rally after its earnings report can sustain through month-end.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:14 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
XRP price today holds near $2 as Binance widens Ripple’s RLUSD rollout and Fed week looms
Previous Story

XRP price today holds near $2 as Binance widens Ripple’s RLUSD rollout and Fed week looms

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings
Next Story

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Go toTop